nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—P-Glycoprotein Inhibitors—Cyclosporine—psoriasis	0.382	1	CiPCiCtD
Vemurafenib—skin cancer—psoriasis	0.356	1	CtDrD
Vemurafenib—ALB—Acitretin—psoriasis	0.0184	0.103	CbGbCtD
Vemurafenib—CYP1A2—Clobetasol propionate—psoriasis	0.0171	0.0958	CbGbCtD
Vemurafenib—ABCC1—Cyclosporine—psoriasis	0.0141	0.0794	CbGbCtD
Vemurafenib—ABCG2—Mycophenolate mofetil—psoriasis	0.0125	0.0701	CbGbCtD
Vemurafenib—ABCG2—Hydrocortisone—psoriasis	0.01	0.0563	CbGbCtD
Vemurafenib—ABCG2—Cyclosporine—psoriasis	0.00946	0.0531	CbGbCtD
Vemurafenib—CYP1A2—Methoxsalen—psoriasis	0.00896	0.0503	CbGbCtD
Vemurafenib—ALB—Mycophenolate mofetil—psoriasis	0.00861	0.0483	CbGbCtD
Vemurafenib—CYP2D6—Hydroxyurea—psoriasis	0.00808	0.0453	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—psoriasis	0.00748	0.042	CbGbCtD
Vemurafenib—ALB—Prednisone—psoriasis	0.00688	0.0386	CbGbCtD
Vemurafenib—ABCG2—Dexamethasone—psoriasis	0.00623	0.035	CbGbCtD
Vemurafenib—CYP3A4—Calcitriol—psoriasis	0.00604	0.0339	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—psoriasis	0.00501	0.0281	CbGbCtD
Vemurafenib—CYP2D6—Cholecalciferol—psoriasis	0.00489	0.0275	CbGbCtD
Vemurafenib—CYP3A4—Methoxsalen—psoriasis	0.0047	0.0264	CbGbCtD
Vemurafenib—ALB—Methotrexate—psoriasis	0.00345	0.0194	CbGbCtD
Vemurafenib—CYP2D6—Cyclosporine—psoriasis	0.00321	0.0181	CbGbCtD
Vemurafenib—CYP3A4—Cholecalciferol—psoriasis	0.00311	0.0175	CbGbCtD
Vemurafenib—CYP3A4—Mycophenolate mofetil—psoriasis	0.0027	0.0151	CbGbCtD
Vemurafenib—CYP3A4—Triamcinolone—psoriasis	0.0027	0.0151	CbGbCtD
Vemurafenib—CYP3A4—Betamethasone—psoriasis	0.00231	0.013	CbGbCtD
Vemurafenib—CYP3A4—Prednisolone—psoriasis	0.00228	0.0128	CbGbCtD
Vemurafenib—CYP3A4—Hydrocortisone—psoriasis	0.00216	0.0122	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—psoriasis	0.00216	0.0121	CbGbCtD
Vemurafenib—CYP2D6—Dexamethasone—psoriasis	0.00212	0.0119	CbGbCtD
Vemurafenib—CYP3A4—Cyclosporine—psoriasis	0.00204	0.0115	CbGbCtD
Vemurafenib—CYP3A4—Dexamethasone—psoriasis	0.00135	0.00756	CbGbCtD
Vemurafenib—Headache—Fluocinolone Acetonide—psoriasis	5.55e-05	0.00093	CcSEcCtD
Vemurafenib—Dysgeusia—Mycophenolate mofetil—psoriasis	5.53e-05	0.000927	CcSEcCtD
Vemurafenib—Eye disorder—Hydrocortisone—psoriasis	5.52e-05	0.000926	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Dexamethasone—psoriasis	5.51e-05	0.000924	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Betamethasone—psoriasis	5.51e-05	0.000924	CcSEcCtD
Vemurafenib—Body temperature increased—Hydroxyurea—psoriasis	5.51e-05	0.000924	CcSEcCtD
Vemurafenib—Back pain—Mycophenolate mofetil—psoriasis	5.46e-05	0.000916	CcSEcCtD
Vemurafenib—Hypotension—Mycophenolic acid—psoriasis	5.45e-05	0.000915	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	5.32e-05	0.000892	CcSEcCtD
Vemurafenib—Nausea—Acitretin—psoriasis	5.27e-05	0.000884	CcSEcCtD
Vemurafenib—Erythema—Prednisolone—psoriasis	5.26e-05	0.000883	CcSEcCtD
Vemurafenib—Nausea—Fluocinolone Acetonide—psoriasis	5.26e-05	0.000882	CcSEcCtD
Vemurafenib—Erythema—Hydrocortisone—psoriasis	5.14e-05	0.000862	CcSEcCtD
Vemurafenib—Malnutrition—Hydrocortisone—psoriasis	5.14e-05	0.000862	CcSEcCtD
Vemurafenib—Hypersensitivity—Hydroxyurea—psoriasis	5.13e-05	0.000861	CcSEcCtD
Vemurafenib—Decreased appetite—Mycophenolic acid—psoriasis	5.07e-05	0.000851	CcSEcCtD
Vemurafenib—Cough—Cyclosporine—psoriasis	5.05e-05	0.000847	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Mycophenolic acid—psoriasis	5.04e-05	0.000845	CcSEcCtD
Vemurafenib—Fatigue—Mycophenolic acid—psoriasis	5.03e-05	0.000844	CcSEcCtD
Vemurafenib—Asthenia—Hydroxyurea—psoriasis	5e-05	0.000839	CcSEcCtD
Vemurafenib—Constipation—Mycophenolic acid—psoriasis	4.99e-05	0.000837	CcSEcCtD
Vemurafenib—Weight decreased—Prednisone—psoriasis	4.97e-05	0.000833	CcSEcCtD
Vemurafenib—Arthralgia—Cyclosporine—psoriasis	4.93e-05	0.000826	CcSEcCtD
Vemurafenib—Myalgia—Cyclosporine—psoriasis	4.93e-05	0.000826	CcSEcCtD
Vemurafenib—Cough—Mycophenolate mofetil—psoriasis	4.93e-05	0.000826	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	4.89e-05	0.00082	CcSEcCtD
Vemurafenib—Erythema—Triamcinolone—psoriasis	4.84e-05	0.000812	CcSEcCtD
Vemurafenib—Arthralgia—Mycophenolate mofetil—psoriasis	4.81e-05	0.000806	CcSEcCtD
Vemurafenib—Myalgia—Mycophenolate mofetil—psoriasis	4.81e-05	0.000806	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—psoriasis	4.8e-05	0.000805	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—psoriasis	4.78e-05	0.000802	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	4.77e-05	0.0008	CcSEcCtD
Vemurafenib—Diarrhoea—Hydroxyurea—psoriasis	4.77e-05	0.0008	CcSEcCtD
Vemurafenib—Dysgeusia—Triamcinolone—psoriasis	4.74e-05	0.000795	CcSEcCtD
Vemurafenib—Anaphylactic shock—Cyclosporine—psoriasis	4.72e-05	0.000792	CcSEcCtD
Vemurafenib—Eye disorder—Dexamethasone—psoriasis	4.72e-05	0.000791	CcSEcCtD
Vemurafenib—Eye disorder—Betamethasone—psoriasis	4.72e-05	0.000791	CcSEcCtD
Vemurafenib—Infection—Cyclosporine—psoriasis	4.69e-05	0.000787	CcSEcCtD
Vemurafenib—Back pain—Triamcinolone—psoriasis	4.68e-05	0.000785	CcSEcCtD
Vemurafenib—Nervous system disorder—Cyclosporine—psoriasis	4.63e-05	0.000777	CcSEcCtD
Vemurafenib—Body temperature increased—Mycophenolic acid—psoriasis	4.61e-05	0.000774	CcSEcCtD
Vemurafenib—Dizziness—Hydroxyurea—psoriasis	4.61e-05	0.000773	CcSEcCtD
Vemurafenib—Anaphylactic shock—Mycophenolate mofetil—psoriasis	4.61e-05	0.000773	CcSEcCtD
Vemurafenib—Skin disorder—Cyclosporine—psoriasis	4.59e-05	0.000769	CcSEcCtD
Vemurafenib—Angiopathy—Betamethasone—psoriasis	4.58e-05	0.000768	CcSEcCtD
Vemurafenib—Angiopathy—Dexamethasone—psoriasis	4.58e-05	0.000768	CcSEcCtD
Vemurafenib—Infection—Mycophenolate mofetil—psoriasis	4.58e-05	0.000768	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—psoriasis	4.54e-05	0.000762	CcSEcCtD
Vemurafenib—Nervous system disorder—Mycophenolate mofetil—psoriasis	4.52e-05	0.000758	CcSEcCtD
Vemurafenib—Skin disorder—Mycophenolate mofetil—psoriasis	4.47e-05	0.00075	CcSEcCtD
Vemurafenib—Alopecia—Dexamethasone—psoriasis	4.46e-05	0.000748	CcSEcCtD
Vemurafenib—Alopecia—Betamethasone—psoriasis	4.46e-05	0.000748	CcSEcCtD
Vemurafenib—Vomiting—Hydroxyurea—psoriasis	4.43e-05	0.000743	CcSEcCtD
Vemurafenib—Rash—Hydroxyurea—psoriasis	4.39e-05	0.000737	CcSEcCtD
Vemurafenib—Erythema—Betamethasone—psoriasis	4.39e-05	0.000737	CcSEcCtD
Vemurafenib—Erythema—Dexamethasone—psoriasis	4.39e-05	0.000737	CcSEcCtD
Vemurafenib—Dermatitis—Hydroxyurea—psoriasis	4.39e-05	0.000736	CcSEcCtD
Vemurafenib—Myalgia—Hydrocortisone—psoriasis	4.38e-05	0.000734	CcSEcCtD
Vemurafenib—Headache—Hydroxyurea—psoriasis	4.37e-05	0.000732	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	4.35e-05	0.000729	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—psoriasis	4.32e-05	0.000724	CcSEcCtD
Vemurafenib—Hypotension—Mycophenolate mofetil—psoriasis	4.3e-05	0.000722	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cyclosporine—psoriasis	4.3e-05	0.000722	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisolone—psoriasis	4.3e-05	0.000721	CcSEcCtD
Vemurafenib—Cough—Triamcinolone—psoriasis	4.22e-05	0.000709	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	4.2e-05	0.000704	CcSEcCtD
Vemurafenib—Anaphylactic shock—Hydrocortisone—psoriasis	4.2e-05	0.000704	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—psoriasis	4.19e-05	0.000702	CcSEcCtD
Vemurafenib—Asthenia—Mycophenolic acid—psoriasis	4.19e-05	0.000702	CcSEcCtD
Vemurafenib—Infection—Hydrocortisone—psoriasis	4.17e-05	0.000699	CcSEcCtD
Vemurafenib—Nausea—Hydroxyurea—psoriasis	4.14e-05	0.000694	CcSEcCtD
Vemurafenib—Pruritus—Mycophenolic acid—psoriasis	4.13e-05	0.000693	CcSEcCtD
Vemurafenib—Myalgia—Triamcinolone—psoriasis	4.12e-05	0.000691	CcSEcCtD
Vemurafenib—Nervous system disorder—Hydrocortisone—psoriasis	4.12e-05	0.00069	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—psoriasis	4.11e-05	0.000689	CcSEcCtD
Vemurafenib—Decreased appetite—Cyclosporine—psoriasis	4.1e-05	0.000688	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—psoriasis	4.09e-05	0.000686	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—psoriasis	4.09e-05	0.000686	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cyclosporine—psoriasis	4.08e-05	0.000684	CcSEcCtD
Vemurafenib—Skin disorder—Hydrocortisone—psoriasis	4.08e-05	0.000684	CcSEcCtD
Vemurafenib—Fatigue—Cyclosporine—psoriasis	4.07e-05	0.000683	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—psoriasis	4.06e-05	0.00068	CcSEcCtD
Vemurafenib—Constipation—Cyclosporine—psoriasis	4.04e-05	0.000677	CcSEcCtD
Vemurafenib—Decreased appetite—Mycophenolate mofetil—psoriasis	4e-05	0.000672	CcSEcCtD
Vemurafenib—Diarrhoea—Mycophenolic acid—psoriasis	3.99e-05	0.00067	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—psoriasis	3.99e-05	0.000669	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	3.98e-05	0.000667	CcSEcCtD
Vemurafenib—Anaphylactic shock—Triamcinolone—psoriasis	3.95e-05	0.000663	CcSEcCtD
Vemurafenib—Constipation—Mycophenolate mofetil—psoriasis	3.94e-05	0.000661	CcSEcCtD
Vemurafenib—Infection—Triamcinolone—psoriasis	3.93e-05	0.000658	CcSEcCtD
Vemurafenib—Hypotension—Hydrocortisone—psoriasis	3.92e-05	0.000658	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—psoriasis	3.88e-05	0.000651	CcSEcCtD
Vemurafenib—Dizziness—Mycophenolic acid—psoriasis	3.86e-05	0.000647	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—psoriasis	3.83e-05	0.000642	CcSEcCtD
Vemurafenib—Erythema—Prednisone—psoriasis	3.83e-05	0.000642	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	3.82e-05	0.000641	CcSEcCtD
Vemurafenib—Myalgia—Dexamethasone—psoriasis	3.74e-05	0.000627	CcSEcCtD
Vemurafenib—Myalgia—Betamethasone—psoriasis	3.74e-05	0.000627	CcSEcCtD
Vemurafenib—Body temperature increased—Cyclosporine—psoriasis	3.73e-05	0.000626	CcSEcCtD
Vemurafenib—Vomiting—Mycophenolic acid—psoriasis	3.71e-05	0.000622	CcSEcCtD
Vemurafenib—Rash—Mycophenolic acid—psoriasis	3.68e-05	0.000617	CcSEcCtD
Vemurafenib—Dermatitis—Mycophenolic acid—psoriasis	3.68e-05	0.000617	CcSEcCtD
Vemurafenib—Headache—Mycophenolic acid—psoriasis	3.66e-05	0.000613	CcSEcCtD
Vemurafenib—Decreased appetite—Hydrocortisone—psoriasis	3.65e-05	0.000612	CcSEcCtD
Vemurafenib—Body temperature increased—Mycophenolate mofetil—psoriasis	3.64e-05	0.000611	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Hydrocortisone—psoriasis	3.62e-05	0.000608	CcSEcCtD
Vemurafenib—Fatigue—Hydrocortisone—psoriasis	3.62e-05	0.000607	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Triamcinolone—psoriasis	3.6e-05	0.000604	CcSEcCtD
Vemurafenib—Anaphylactic shock—Dexamethasone—psoriasis	3.59e-05	0.000601	CcSEcCtD
Vemurafenib—Anaphylactic shock—Betamethasone—psoriasis	3.59e-05	0.000601	CcSEcCtD
Vemurafenib—Infection—Betamethasone—psoriasis	3.56e-05	0.000597	CcSEcCtD
Vemurafenib—Infection—Dexamethasone—psoriasis	3.56e-05	0.000597	CcSEcCtD
Vemurafenib—Nervous system disorder—Betamethasone—psoriasis	3.52e-05	0.00059	CcSEcCtD
Vemurafenib—Nervous system disorder—Dexamethasone—psoriasis	3.52e-05	0.00059	CcSEcCtD
Vemurafenib—Hypersensitivity—Cyclosporine—psoriasis	3.48e-05	0.000583	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—psoriasis	3.47e-05	0.000582	CcSEcCtD
Vemurafenib—Nausea—Mycophenolic acid—psoriasis	3.47e-05	0.000581	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—psoriasis	3.43e-05	0.000576	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—psoriasis	3.41e-05	0.000572	CcSEcCtD
Vemurafenib—Fatigue—Triamcinolone—psoriasis	3.41e-05	0.000571	CcSEcCtD
Vemurafenib—Hypersensitivity—Mycophenolate mofetil—psoriasis	3.39e-05	0.000569	CcSEcCtD
Vemurafenib—Asthenia—Cyclosporine—psoriasis	3.39e-05	0.000568	CcSEcCtD
Vemurafenib—Hypotension—Dexamethasone—psoriasis	3.35e-05	0.000562	CcSEcCtD
Vemurafenib—Hypotension—Betamethasone—psoriasis	3.35e-05	0.000562	CcSEcCtD
Vemurafenib—Pruritus—Cyclosporine—psoriasis	3.34e-05	0.00056	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—psoriasis	3.33e-05	0.000559	CcSEcCtD
Vemurafenib—Body temperature increased—Hydrocortisone—psoriasis	3.32e-05	0.000556	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—psoriasis	3.31e-05	0.000555	CcSEcCtD
Vemurafenib—Asthenia—Mycophenolate mofetil—psoriasis	3.3e-05	0.000554	CcSEcCtD
Vemurafenib—Chills—Methotrexate—psoriasis	3.3e-05	0.000553	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dexamethasone—psoriasis	3.27e-05	0.000548	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Betamethasone—psoriasis	3.27e-05	0.000548	CcSEcCtD
Vemurafenib—Pruritus—Mycophenolate mofetil—psoriasis	3.26e-05	0.000547	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—psoriasis	3.26e-05	0.000546	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—psoriasis	3.26e-05	0.000546	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—psoriasis	3.25e-05	0.000544	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	3.23e-05	0.000543	CcSEcCtD
Vemurafenib—Diarrhoea—Cyclosporine—psoriasis	3.23e-05	0.000542	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—psoriasis	3.2e-05	0.000536	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—psoriasis	3.2e-05	0.000536	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisolone—psoriasis	3.17e-05	0.000531	CcSEcCtD
Vemurafenib—Diarrhoea—Mycophenolate mofetil—psoriasis	3.15e-05	0.000529	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—psoriasis	3.13e-05	0.000525	CcSEcCtD
Vemurafenib—Body temperature increased—Triamcinolone—psoriasis	3.12e-05	0.000524	CcSEcCtD
Vemurafenib—Dizziness—Cyclosporine—psoriasis	3.12e-05	0.000524	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—psoriasis	3.12e-05	0.000524	CcSEcCtD
Vemurafenib—Decreased appetite—Dexamethasone—psoriasis	3.12e-05	0.000523	CcSEcCtD
Vemurafenib—Decreased appetite—Betamethasone—psoriasis	3.12e-05	0.000523	CcSEcCtD
Vemurafenib—Infection—Prednisone—psoriasis	3.1e-05	0.00052	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Betamethasone—psoriasis	3.1e-05	0.000519	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Dexamethasone—psoriasis	3.1e-05	0.000519	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—psoriasis	3.09e-05	0.000519	CcSEcCtD
Vemurafenib—Hypersensitivity—Hydrocortisone—psoriasis	3.09e-05	0.000519	CcSEcCtD
Vemurafenib—Fatigue—Betamethasone—psoriasis	3.09e-05	0.000518	CcSEcCtD
Vemurafenib—Fatigue—Dexamethasone—psoriasis	3.09e-05	0.000518	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—psoriasis	3.06e-05	0.000514	CcSEcCtD
Vemurafenib—Dizziness—Mycophenolate mofetil—psoriasis	3.05e-05	0.000511	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—psoriasis	3.03e-05	0.000509	CcSEcCtD
Vemurafenib—Asthenia—Hydrocortisone—psoriasis	3.01e-05	0.000505	CcSEcCtD
Vemurafenib—Vomiting—Cyclosporine—psoriasis	3e-05	0.000504	CcSEcCtD
Vemurafenib—Rash—Cyclosporine—psoriasis	2.98e-05	0.000499	CcSEcCtD
Vemurafenib—Dermatitis—Cyclosporine—psoriasis	2.97e-05	0.000499	CcSEcCtD
Vemurafenib—Pruritus—Hydrocortisone—psoriasis	2.97e-05	0.000498	CcSEcCtD
Vemurafenib—Headache—Cyclosporine—psoriasis	2.96e-05	0.000496	CcSEcCtD
Vemurafenib—Vomiting—Mycophenolate mofetil—psoriasis	2.93e-05	0.000491	CcSEcCtD
Vemurafenib—Hypersensitivity—Triamcinolone—psoriasis	2.91e-05	0.000488	CcSEcCtD
Vemurafenib—Rash—Mycophenolate mofetil—psoriasis	2.9e-05	0.000487	CcSEcCtD
Vemurafenib—Dermatitis—Mycophenolate mofetil—psoriasis	2.9e-05	0.000487	CcSEcCtD
Vemurafenib—Headache—Mycophenolate mofetil—psoriasis	2.89e-05	0.000484	CcSEcCtD
Vemurafenib—Diarrhoea—Hydrocortisone—psoriasis	2.87e-05	0.000482	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—psoriasis	2.84e-05	0.000477	CcSEcCtD
Vemurafenib—Dizziness—Prednisolone—psoriasis	2.84e-05	0.000477	CcSEcCtD
Vemurafenib—Asthenia—Triamcinolone—psoriasis	2.84e-05	0.000475	CcSEcCtD
Vemurafenib—Body temperature increased—Betamethasone—psoriasis	2.83e-05	0.000475	CcSEcCtD
Vemurafenib—Body temperature increased—Dexamethasone—psoriasis	2.83e-05	0.000475	CcSEcCtD
Vemurafenib—Nausea—Cyclosporine—psoriasis	2.8e-05	0.00047	CcSEcCtD
Vemurafenib—Pruritus—Triamcinolone—psoriasis	2.8e-05	0.000469	CcSEcCtD
Vemurafenib—Cough—Methotrexate—psoriasis	2.79e-05	0.000468	CcSEcCtD
Vemurafenib—Dizziness—Hydrocortisone—psoriasis	2.78e-05	0.000465	CcSEcCtD
Vemurafenib—Nausea—Mycophenolate mofetil—psoriasis	2.74e-05	0.000459	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—psoriasis	2.72e-05	0.000457	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—psoriasis	2.72e-05	0.000457	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—psoriasis	2.71e-05	0.000455	CcSEcCtD
Vemurafenib—Rash—Prednisolone—psoriasis	2.71e-05	0.000454	CcSEcCtD
Vemurafenib—Dermatitis—Prednisolone—psoriasis	2.71e-05	0.000454	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	2.7e-05	0.000453	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—psoriasis	2.69e-05	0.000451	CcSEcCtD
Vemurafenib—Headache—Prednisolone—psoriasis	2.69e-05	0.000451	CcSEcCtD
Vemurafenib—Constipation—Prednisone—psoriasis	2.67e-05	0.000448	CcSEcCtD
Vemurafenib—Vomiting—Hydrocortisone—psoriasis	2.67e-05	0.000447	CcSEcCtD
Vemurafenib—Rash—Hydrocortisone—psoriasis	2.65e-05	0.000444	CcSEcCtD
Vemurafenib—Dermatitis—Hydrocortisone—psoriasis	2.64e-05	0.000443	CcSEcCtD
Vemurafenib—Headache—Hydrocortisone—psoriasis	2.63e-05	0.000441	CcSEcCtD
Vemurafenib—Dizziness—Triamcinolone—psoriasis	2.61e-05	0.000438	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—psoriasis	2.61e-05	0.000438	CcSEcCtD
Vemurafenib—Infection—Methotrexate—psoriasis	2.59e-05	0.000435	CcSEcCtD
Vemurafenib—Asthenia—Dexamethasone—psoriasis	2.57e-05	0.000431	CcSEcCtD
Vemurafenib—Asthenia—Betamethasone—psoriasis	2.57e-05	0.000431	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—psoriasis	2.56e-05	0.000429	CcSEcCtD
Vemurafenib—Nausea—Prednisolone—psoriasis	2.55e-05	0.000428	CcSEcCtD
Vemurafenib—Pruritus—Dexamethasone—psoriasis	2.54e-05	0.000425	CcSEcCtD
Vemurafenib—Pruritus—Betamethasone—psoriasis	2.54e-05	0.000425	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—psoriasis	2.53e-05	0.000425	CcSEcCtD
Vemurafenib—Vomiting—Triamcinolone—psoriasis	2.51e-05	0.000421	CcSEcCtD
Vemurafenib—Nausea—Hydrocortisone—psoriasis	2.49e-05	0.000418	CcSEcCtD
Vemurafenib—Rash—Triamcinolone—psoriasis	2.49e-05	0.000418	CcSEcCtD
Vemurafenib—Dermatitis—Triamcinolone—psoriasis	2.49e-05	0.000417	CcSEcCtD
Vemurafenib—Headache—Triamcinolone—psoriasis	2.48e-05	0.000415	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—psoriasis	2.47e-05	0.000414	CcSEcCtD
Vemurafenib—Diarrhoea—Dexamethasone—psoriasis	2.45e-05	0.000411	CcSEcCtD
Vemurafenib—Diarrhoea—Betamethasone—psoriasis	2.45e-05	0.000411	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—psoriasis	2.44e-05	0.000409	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—psoriasis	2.38e-05	0.000399	CcSEcCtD
Vemurafenib—Dizziness—Betamethasone—psoriasis	2.37e-05	0.000398	CcSEcCtD
Vemurafenib—Dizziness—Dexamethasone—psoriasis	2.37e-05	0.000398	CcSEcCtD
Vemurafenib—Nausea—Triamcinolone—psoriasis	2.35e-05	0.000394	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—psoriasis	2.3e-05	0.000386	CcSEcCtD
Vemurafenib—Vomiting—Betamethasone—psoriasis	2.28e-05	0.000382	CcSEcCtD
Vemurafenib—Vomiting—Dexamethasone—psoriasis	2.28e-05	0.000382	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—psoriasis	2.27e-05	0.00038	CcSEcCtD
Vemurafenib—Rash—Betamethasone—psoriasis	2.26e-05	0.000379	CcSEcCtD
Vemurafenib—Rash—Dexamethasone—psoriasis	2.26e-05	0.000379	CcSEcCtD
Vemurafenib—Dermatitis—Betamethasone—psoriasis	2.26e-05	0.000379	CcSEcCtD
Vemurafenib—Dermatitis—Dexamethasone—psoriasis	2.26e-05	0.000379	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—psoriasis	2.25e-05	0.000378	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—psoriasis	2.25e-05	0.000377	CcSEcCtD
Vemurafenib—Headache—Dexamethasone—psoriasis	2.25e-05	0.000377	CcSEcCtD
Vemurafenib—Headache—Betamethasone—psoriasis	2.25e-05	0.000377	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—psoriasis	2.24e-05	0.000376	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—psoriasis	2.21e-05	0.00037	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—psoriasis	2.14e-05	0.000358	CcSEcCtD
Vemurafenib—Nausea—Dexamethasone—psoriasis	2.13e-05	0.000357	CcSEcCtD
Vemurafenib—Nausea—Betamethasone—psoriasis	2.13e-05	0.000357	CcSEcCtD
Vemurafenib—BRAF—MAPK Signaling Pathway—TNF—psoriasis	2.08e-05	0.000834	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—HCAR2—psoriasis	2.07e-05	0.000829	CbGpPWpGaD
Vemurafenib—Dizziness—Prednisone—psoriasis	2.06e-05	0.000346	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—psoriasis	2.06e-05	0.000346	CcSEcCtD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	2.04e-05	0.000818	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.04e-05	0.000817	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.03e-05	0.000815	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—DDX58—psoriasis	2.02e-05	0.000811	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—HLA-DRB1—psoriasis	2.02e-05	0.000811	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—TYK2—psoriasis	2.01e-05	0.000808	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—TNF—psoriasis	2.01e-05	0.000806	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IFNG—psoriasis	2e-05	0.000805	CbGpPWpGaD
Vemurafenib—RAF1—IRS-mediated signalling—IL6—psoriasis	2e-05	0.000803	CbGpPWpGaD
Vemurafenib—RAF1—Insulin Signaling—JUN—psoriasis	2e-05	0.000801	CbGpPWpGaD
Vemurafenib—BRAF—Integrated Breast Cancer Pathway—TP53—psoriasis	1.99e-05	0.0008	CbGpPWpGaD
Vemurafenib—Vomiting—Prednisone—psoriasis	1.99e-05	0.000333	CcSEcCtD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—JUN—psoriasis	1.98e-05	0.000793	CbGpPWpGaD
Vemurafenib—Rash—Prednisone—psoriasis	1.97e-05	0.00033	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—psoriasis	1.97e-05	0.00033	CcSEcCtD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	1.96e-05	0.000787	CbGpPWpGaD
Vemurafenib—Headache—Prednisone—psoriasis	1.96e-05	0.000328	CcSEcCtD
Vemurafenib—ABCG2—Metabolism—CYP2S1—psoriasis	1.95e-05	0.000782	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	1.95e-05	0.000781	CbGpPWpGaD
Vemurafenib—RAF1—IRS-related events—IL6—psoriasis	1.95e-05	0.000781	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—ICAM1—psoriasis	1.94e-05	0.000778	CbGpPWpGaD
Vemurafenib—RAF1—IRS-related events triggered by IGF1R—IL6—psoriasis	1.93e-05	0.000774	CbGpPWpGaD
Vemurafenib—Hypersensitivity—Methotrexate—psoriasis	1.92e-05	0.000322	CcSEcCtD
Vemurafenib—RAF1—MAPK Signaling Pathway—JUN—psoriasis	1.92e-05	0.00077	CbGpPWpGaD
Vemurafenib—RAF1—TCR Signaling Pathway—IL6—psoriasis	1.91e-05	0.000767	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—STAT3—psoriasis	1.91e-05	0.000767	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—NFKBIA—psoriasis	1.89e-05	0.000759	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HLA-E—psoriasis	1.88e-05	0.000754	CbGpPWpGaD
Vemurafenib—RAF1—BDNF signaling pathway—STAT3—psoriasis	1.88e-05	0.000754	CbGpPWpGaD
Vemurafenib—RAF1—Insulin receptor signalling cascade—IL6—psoriasis	1.88e-05	0.000754	CbGpPWpGaD
Vemurafenib—RAF1—TNF alpha Signaling Pathway—IL6—psoriasis	1.88e-05	0.000754	CbGpPWpGaD
Vemurafenib—RAF1—IGF1R signaling cascade—IL6—psoriasis	1.88e-05	0.000754	CbGpPWpGaD
Vemurafenib—Asthenia—Methotrexate—psoriasis	1.87e-05	0.000314	CcSEcCtD
Vemurafenib—Nausea—Prednisone—psoriasis	1.85e-05	0.000311	CcSEcCtD
Vemurafenib—RAF1—MAPK Signaling Pathway—NFKB1—psoriasis	1.85e-05	0.000741	CbGpPWpGaD
Vemurafenib—Pruritus—Methotrexate—psoriasis	1.85e-05	0.00031	CcSEcCtD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—TP53—psoriasis	1.85e-05	0.000741	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—JUN—psoriasis	1.84e-05	0.000739	CbGpPWpGaD
Vemurafenib—BRAF—MAPK Signaling Pathway—TP53—psoriasis	1.83e-05	0.000735	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL20—psoriasis	1.82e-05	0.000729	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-E—psoriasis	1.8e-05	0.000724	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TAGAP—psoriasis	1.79e-05	0.000719	CbGpPWpGaD
Vemurafenib—Diarrhoea—Methotrexate—psoriasis	1.79e-05	0.000299	CcSEcCtD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	1.78e-05	0.000714	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—NFKB1—psoriasis	1.77e-05	0.000711	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—NFKB1—psoriasis	1.74e-05	0.0007	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—JUN—psoriasis	1.74e-05	0.000698	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.73e-05	0.000695	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR—IL6—psoriasis	1.73e-05	0.000693	CbGpPWpGaD
Vemurafenib—Dizziness—Methotrexate—psoriasis	1.73e-05	0.000289	CcSEcCtD
Vemurafenib—RAF1—Downstream signal transduction—STAT3—psoriasis	1.72e-05	0.000689	CbGpPWpGaD
Vemurafenib—RAF1—EGF/EGFR Signaling Pathway—STAT3—psoriasis	1.71e-05	0.000686	CbGpPWpGaD
Vemurafenib—RAF1—Senescence and Autophagy in Cancer—IL6—psoriasis	1.69e-05	0.000678	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	1.67e-05	0.000669	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.67e-05	0.000669	CbGpPWpGaD
Vemurafenib—RAF1—VEGFA-VEGFR2 Pathway—IL6—psoriasis	1.66e-05	0.000668	CbGpPWpGaD
Vemurafenib—Vomiting—Methotrexate—psoriasis	1.66e-05	0.000278	CcSEcCtD
Vemurafenib—RAF1—Signaling by Interleukins—IL6—psoriasis	1.65e-05	0.000663	CbGpPWpGaD
Vemurafenib—Rash—Methotrexate—psoriasis	1.65e-05	0.000276	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—psoriasis	1.64e-05	0.000276	CcSEcCtD
Vemurafenib—Headache—Methotrexate—psoriasis	1.63e-05	0.000274	CcSEcCtD
Vemurafenib—ALB—Platelet degranulation—VEGFA—psoriasis	1.63e-05	0.000656	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TNF—psoriasis	1.63e-05	0.000655	CbGpPWpGaD
Vemurafenib—ALB—Vitamin B12 Metabolism—IL6—psoriasis	1.62e-05	0.00065	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by FGFR in disease—IL6—psoriasis	1.61e-05	0.000645	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—STAT3—psoriasis	1.59e-05	0.000639	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—TYK2—psoriasis	1.58e-05	0.000632	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ITGAL—psoriasis	1.57e-05	0.000631	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by VEGF—IL6—psoriasis	1.57e-05	0.00063	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—SOCS1—psoriasis	1.57e-05	0.00063	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—STAT3—psoriasis	1.57e-05	0.000629	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by Insulin receptor—IL6—psoriasis	1.56e-05	0.000626	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—STAT3—psoriasis	1.56e-05	0.000625	CbGpPWpGaD
Vemurafenib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	1.56e-05	0.000625	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL20—psoriasis	1.55e-05	0.000622	CbGpPWpGaD
Vemurafenib—Nausea—Methotrexate—psoriasis	1.55e-05	0.00026	CcSEcCtD
Vemurafenib—RAF1—Signaling by NGF—TYK2—psoriasis	1.55e-05	0.000622	CbGpPWpGaD
Vemurafenib—RAF1—TGF-beta Signaling Pathway—TP53—psoriasis	1.54e-05	0.000617	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ITGAL—psoriasis	1.53e-05	0.000615	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	1.53e-05	0.000612	CbGpPWpGaD
Vemurafenib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	1.53e-05	0.000612	CbGpPWpGaD
Vemurafenib—RAF1—Focal Adhesion—VEGFA—psoriasis	1.52e-05	0.00061	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.51e-05	0.000607	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—SOCS1—psoriasis	1.51e-05	0.000605	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IFNG—psoriasis	1.48e-05	0.000592	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—TP53—psoriasis	1.44e-05	0.000578	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TNF—psoriasis	1.44e-05	0.000577	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—REL—psoriasis	1.43e-05	0.000575	CbGpPWpGaD
Vemurafenib—BRAF—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	1.42e-05	0.000571	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—NDUFA5—psoriasis	1.41e-05	0.000568	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—STAT3—psoriasis	1.41e-05	0.000566	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—TYK2—psoriasis	1.4e-05	0.000563	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFIH1—psoriasis	1.39e-05	0.000558	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.35e-05	0.00054	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—HLA-B—psoriasis	1.34e-05	0.000537	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD8A—psoriasis	1.34e-05	0.000536	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by SCF-KIT—IL6—psoriasis	1.33e-05	0.000535	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.32e-05	0.000529	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-C—psoriasis	1.32e-05	0.000529	CbGpPWpGaD
Vemurafenib—ALB—Folate Metabolism—IL6—psoriasis	1.32e-05	0.000529	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—CP—psoriasis	1.31e-05	0.000527	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—LEP—psoriasis	1.31e-05	0.000526	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TNFAIP3—psoriasis	1.3e-05	0.000523	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—TNF—psoriasis	1.3e-05	0.000521	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.3e-05	0.00052	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-B—psoriasis	1.29e-05	0.000516	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—IL6—psoriasis	1.28e-05	0.000512	CbGpPWpGaD
Vemurafenib—RAF1—MAPK Signaling Pathway—TP53—psoriasis	1.27e-05	0.000508	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—IL6—psoriasis	1.26e-05	0.000504	CbGpPWpGaD
Vemurafenib—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	1.25e-05	0.000503	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—NFKB1—psoriasis	1.23e-05	0.000493	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—NFKB1—psoriasis	1.21e-05	0.000484	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP2S1—psoriasis	1.2e-05	0.000483	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—psoriasis	1.2e-05	0.000482	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—NOS2—psoriasis	1.2e-05	0.000481	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—psoriasis	1.19e-05	0.000479	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-A—psoriasis	1.19e-05	0.000478	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—psoriasis	1.19e-05	0.000477	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CRP—psoriasis	1.18e-05	0.000475	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—psoriasis	1.18e-05	0.000475	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—NDUFA5—psoriasis	1.17e-05	0.000469	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.16e-05	0.000466	CbGpPWpGaD
Vemurafenib—RAF1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.14e-05	0.000459	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—PPARG—psoriasis	1.14e-05	0.000458	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—psoriasis	1.11e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—psoriasis	1.11e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	1.11e-05	0.000446	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—STAT3—psoriasis	1.1e-05	0.000443	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—psoriasis	1.1e-05	0.000442	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—psoriasis	1.1e-05	0.00044	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-E—psoriasis	1.09e-05	0.000439	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—psoriasis	1.09e-05	0.000439	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DRB1—psoriasis	1.09e-05	0.000437	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—psoriasis	1.09e-05	0.000437	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—STAT3—psoriasis	1.08e-05	0.000435	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CARM1—psoriasis	1.08e-05	0.000434	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NFKBIA—psoriasis	1.08e-05	0.000433	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL20—psoriasis	1.07e-05	0.000431	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.05e-05	0.00042	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ICAM1—psoriasis	1.04e-05	0.000419	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NFKBIA—psoriasis	1.04e-05	0.000416	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.01e-05	0.000406	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TYK2—psoriasis	1e-05	0.000402	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP2S1—psoriasis	9.93e-06	0.000398	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—VEGFA—psoriasis	9.92e-06	0.000398	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—NDUFA5—psoriasis	9.89e-06	0.000397	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	9.85e-06	0.000395	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HLA-A—psoriasis	9.64e-06	0.000387	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	9.52e-06	0.000382	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CARM1—psoriasis	9.52e-06	0.000382	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	9.22e-06	0.00037	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—SOCS1—psoriasis	9.14e-06	0.000367	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APOE—psoriasis	9e-06	0.000361	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TYK2—psoriasis	8.84e-06	0.000355	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SOCS1—psoriasis	8.54e-06	0.000343	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP2S1—psoriasis	8.41e-06	0.000338	CbGpPWpGaD
Vemurafenib—BRAF—Disease—NOS2—psoriasis	8.39e-06	0.000337	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—psoriasis	8.1e-06	0.000325	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—psoriasis	7.99e-06	0.000321	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—NFKB1—psoriasis	7.8e-06	0.000313	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-B—psoriasis	7.8e-06	0.000313	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—psoriasis	7.71e-06	0.000309	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—psoriasis	7.67e-06	0.000308	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—NDUFA5—psoriasis	7.63e-06	0.000306	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—psoriasis	7.58e-06	0.000304	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	7.25e-06	0.000291	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-A—psoriasis	7.22e-06	0.00029	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—JUN—psoriasis	7.15e-06	0.000287	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—VEGFA—psoriasis	7.08e-06	0.000284	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—STAT3—psoriasis	7.01e-06	0.000281	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—VEGFA—psoriasis	6.94e-06	0.000279	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CRP—psoriasis	6.89e-06	0.000277	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—NFKB1—psoriasis	6.89e-06	0.000276	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TYK2—psoriasis	6.87e-06	0.000276	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—psoriasis	6.86e-06	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HLA-A—psoriasis	6.67e-06	0.000268	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—CAT—psoriasis	6.65e-06	0.000267	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—NFKB1—psoriasis	6.61e-06	0.000265	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HLA-A—psoriasis	6.61e-06	0.000265	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DRB1—psoriasis	6.6e-06	0.000265	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP2S1—psoriasis	6.49e-06	0.00026	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—NOS2—psoriasis	6.45e-06	0.000259	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ICAM1—psoriasis	6.33e-06	0.000254	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—LEP—psoriasis	6.3e-06	0.000253	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APOE—psoriasis	6.3e-06	0.000253	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.3e-06	0.000253	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NFKBIA—psoriasis	6.28e-06	0.000252	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOE—psoriasis	6.23e-06	0.00025	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—psoriasis	6.21e-06	0.000249	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOE—psoriasis	6.17e-06	0.000248	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—psoriasis	6.06e-06	0.000243	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SOCS1—psoriasis	5.91e-06	0.000237	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NFKBIA—psoriasis	5.87e-06	0.000236	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CARM1—psoriasis	5.87e-06	0.000236	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—CAT—psoriasis	5.85e-06	0.000235	CbGpPWpGaD
Vemurafenib—RAF1—Disease—NOS2—psoriasis	5.8e-06	0.000233	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—NOS2—psoriasis	5.75e-06	0.000231	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TYK2—psoriasis	5.63e-06	0.000226	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.49e-06	0.00022	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TP53—psoriasis	5.24e-06	0.00021	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—psoriasis	5.17e-06	0.000207	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TYK2—psoriasis	5.15e-06	0.000207	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL8—psoriasis	4.9e-06	0.000197	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—psoriasis	4.89e-06	0.000196	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CARM1—psoriasis	4.85e-06	0.000195	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—psoriasis	4.82e-06	0.000193	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TYK2—psoriasis	4.81e-06	0.000193	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—psoriasis	4.81e-06	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TYK2—psoriasis	4.75e-06	0.000191	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TYK2—psoriasis	4.71e-06	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—psoriasis	4.65e-06	0.000187	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—psoriasis	4.55e-06	0.000183	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—PPARG—psoriasis	4.5e-06	0.000181	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.41e-06	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—LEP—psoriasis	4.36e-06	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—psoriasis	4.36e-06	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—psoriasis	4.32e-06	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—psoriasis	4.3e-06	0.000172	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—psoriasis	4.26e-06	0.000171	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL8—psoriasis	4.19e-06	0.000168	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—JUN—psoriasis	4.17e-06	0.000167	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CARM1—psoriasis	4.11e-06	0.000165	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKBIA—psoriasis	4.06e-06	0.000163	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—NFKB1—psoriasis	4.01e-06	0.000161	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—PPARG—psoriasis	3.96e-06	0.000159	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—JUN—psoriasis	3.89e-06	0.000156	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.84e-06	0.000154	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—NFKB1—psoriasis	3.75e-06	0.00015	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—VEGFA—psoriasis	3.74e-06	0.00015	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CAT—psoriasis	3.61e-06	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—psoriasis	3.6e-06	0.000145	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—VEGFA—psoriasis	3.4e-06	0.000136	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—psoriasis	3.37e-06	0.000135	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—psoriasis	3.36e-06	0.000135	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TYK2—psoriasis	3.33e-06	0.000134	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—psoriasis	3.33e-06	0.000134	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—psoriasis	3.3e-06	0.000132	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CARM1—psoriasis	3.17e-06	0.000127	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CAT—psoriasis	2.98e-06	0.00012	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL8—psoriasis	2.9e-06	0.000116	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TP53—psoriasis	2.82e-06	0.000113	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—psoriasis	2.81e-06	0.000113	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—psoriasis	2.76e-06	0.000111	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—JUN—psoriasis	2.69e-06	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—NFKB1—psoriasis	2.59e-06	0.000104	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TP53—psoriasis	2.57e-06	0.000103	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CAT—psoriasis	2.53e-06	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—psoriasis	2.52e-06	0.000101	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—PPARG—psoriasis	2.44e-06	9.81e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—VEGFA—psoriasis	2.35e-06	9.44e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—psoriasis	2.35e-06	9.44e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—psoriasis	2.33e-06	9.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—psoriasis	2.32e-06	9.33e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—psoriasis	2.32e-06	9.3e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—psoriasis	2.3e-06	9.25e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—PPARG—psoriasis	2.02e-06	8.1e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—psoriasis	1.96e-06	7.88e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CAT—psoriasis	1.95e-06	7.82e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TP53—psoriasis	1.78e-06	7.14e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—PPARG—psoriasis	1.71e-06	6.86e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—psoriasis	1.63e-06	6.53e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—psoriasis	1.51e-06	6.08e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—PPARG—psoriasis	1.32e-06	5.3e-05	CbGpPWpGaD
